Business context and reporting period
Stellus Capital Investment Corporation (NYSE: SCM) is an externally managed business development company (BDC) and regulated investment company (RIC) that lends to and takes related equity positions in U.S. middle-market businesses. This unaudited Form 10-Q covers the quarter ended March 31, 2024; operating results are compared with the three months ended March 31, 2023, while balance-sheet changes are generally compared with December 31, 2023.
Key financial metrics
| Metric | Q1 2024 / March 31, 2024 | Comparable figure |
|---|---|---|
| Investment income | $26.0 million | $24.1 million in Q1 2023 |
| Net investment income | $10.2 million; $0.42 per share | $9.1 million; $0.46 per share in Q1 2023 |
| Net increase in net assets from operations | $13.1 million; $0.54 per share | $4.7 million; $0.24 per share in Q1 2023 |
| Distributions | $0.40 per share for the quarter | $0.40 per share in Q1 2023 |
| Net asset value (NAV) per share | $13.41 | $13.26 at December 31, 2023; $13.87 at March 31, 2023 |
| Portfolio fair value | $875.9 million across 94 portfolio companies | $874.5 million across 93 companies at December 31, 2023 |
| Cash and cash equivalents | $48.8 million | $26.1 million at December 31, 2023 |
| Debt outstanding, principal amounts | $100.0 million notes, $184.7 million credit facility, and $325.0 million SBA debentures | Credit facility was $160.1 million at December 31, 2023; notes and SBA debentures were unchanged |
| Asset coverage ratio | 214% | 223% at December 31, 2023 |
| Operating cash flow | $4.5 million provided | $32.0 million used in Q1 2023 |
Reported operating expenses were $16.0 million, or $15.8 million net of a $0.2 million income incentive fee waiver. The filing does not present a single operating margin measure; net investment income was approximately 39% of investment income. Debt investments were approximately 98% floating-rate. Portfolio fair value was entirely Level 3, relying on significant unobservable valuation inputs.
Material changes versus comparable periods
- Investment income rose about 8% year over year, which management attributed primarily to portfolio growth and higher interest rates. Net investment income increased in dollars, but declined per share from $0.46 to $0.42; weighted-average shares rose from 19.8 million to 24.1 million.
- Net operating results improved year over year, principally because unrealized appreciation was $23.5 million versus $4.2 million of unrealized depreciation in Q1 2023. This was partly offset by a $20.4 million net realized investment loss, compared with a small realized gain in Q1 2023.
- Credit-facility borrowings increased by about $24.6 million from year-end, while cash increased by about $22.6 million. Total portfolio fair value rose slightly, although investment cost declined.
- First-lien investments increased to approximately 90% of portfolio fair value, while second-lien investments declined to approximately 1% from 2% at year-end. Equity remained about 8%.
- Four loans were on non-accrual at both March 31, 2024 and December 31, 2023. The company reported Q1 non-accrual loans at 3.7% of loan cost and 2.1% of loan fair value; prior-period percentages differ between filing sections and should be verified.
Outlook, commentary, risks and unusual items
- No quantitative earnings or portfolio-growth guidance is provided. Management says investment activity varies with capital availability, M&A activity, economic conditions and competition. It cited supply-chain and labor constraints, commodity inflation, higher interest rates, bank impairments and failures, sanctions, and geopolitical and market instability.
- Management reported sufficient liquidity to meet $34.1 million of unfunded debt commitments and $0.3 million of unfunded equity commitments as of March 31, 2024. The credit facility requires at least $10 million of liquidity and includes leverage, equity and interest-coverage covenants; the company reported compliance.
- Interest-rate sensitivity analysis estimates that a 100-basis-point increase would raise annual net interest income by $6.1 million, while a 100-basis-point decrease would reduce it by $6.1 million, before incentive-fee effects. The filing cautions that actual results could differ as portfolio composition and credit quality change.
- Key risks include borrower credit deterioration, illiquid investments and subjective fair-value estimates, leverage and financing costs, interest-rate volatility, the ability to raise capital, and meeting BDC/RIC requirements and distribution obligations. The company reported a 214% asset coverage ratio against its 150% statutory minimum; the credit facility separately requires at least 1.67-to-1 coverage.
- Valuation and credit items merit attention: the $20.4 million realized loss and $23.5 million unrealized appreciation materially affected reported results. Certain portfolio loans are non-accrual; $3.0 million of income associated with non-accrual investments had not been accrued at quarter-end. Unrealized marks may not be realized.
- After quarter-end, Stellus made new and add-on investments, including a $7.6 million first-lien investment in FairWave Holdings and a $2.7 million first-lien investment in WER Holdings. Nutritional Medicinals repaid its first-lien loan on May 1 for $11.4 million; the company also received $3.0 million from an equity realization with a $2.0 million realized gain. Credit-facility borrowings were $172.5 million on May 9.
- The board declared monthly dividends of $0.1333 per share for April, May and June 2024. No material legal proceedings were reported, and management said there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Reconcile the prior-period non-accrual percentages: the notes report 4.2% of loan cost and 1.3% of fair value at December 31, 2023, while MD&A reports 5.2% and 2.3%.
- Review the $20.4 million realized investment loss, including the relevant borrower exposures, recoveries and effect on remaining portfolio marks.
- Assess the assumptions and sensitivity behind Level 3 valuations, given that all portfolio investments use significant unobservable inputs.
- Track floating-rate exposure, funding costs, credit-facility utilization and headroom against both contractual covenants and the statutory asset-coverage minimum.
- Compare net investment income per share with the $0.40 quarterly distribution and monitor the effects of share count, incentive fees, fee waivers and future taxable income.